Sensei Biotherapeutics reports FY25 EPS ($16.72) vs ($24.01) last year

“2025 was a year of focus and discipline for Sensei, and with the addition of Faeth and injection of new capital, we are entering 2026 with a clear path forward,” said Christopher Gerry, President & General Counsel of Sensei Biotherapeutics (SNSE). “We are now focused on advancing PIKTOR through key clinical milestones, including topline data from the ongoing Phase 2 trial in advanced endometrial cancer and initiation of the planned Phase 1b trial in HR+/HER2- advanced breast cancer, both expected by year-end 2026.”